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Urinary collagen degradation products 
as early markers of progressive renal fibrosis
Ryanne S. Hijmans1*, Daniel Guldager Kring Rasmussen3,4, Saleh Yazdani1, Gerjan Navis1, Harry van Goor2, 
Morten Asser Karsdal3, Federica Genovese3 and Jacob van den Born1
Abstract 
Background: Renal fibrogenesis is associated with increased ECM remodeling and release of collagen fragments in 
urine in progressive renal disease. We investigated the diagnostic value of urinary collagen degradation products in a 
proteinuria-driven fibrosis rat model with and without anti-fibrotic S1P-receptor modulator FTY720 treatment.
Methods: Proteinuria was induced in male Wistar rats by Adriamycin (ADR) injection (n = 16). Healthy rats served 
as controls (n = 12). Six weeks post-injection, all underwent renal biopsy, and FTY720-treatment started in ADR-rats 
(n = 8) and controls (n = 6). Others remained untreated. Rats were sacrificed after 12 weeks. Collagen type I (C1M) 
and III (C3M) degradation fragments were measured in blood and urine using ELISA. Kidneys were stained for various 
inflammatory and fibrotic markers.
Results: Six weeks post-injection proteinuria increased (versus controls, P < 0.001) and although no accumulation 
of interstitial renal collagen type III (iColl3) was observed at this time, urinary C3M (uC3M) and C1M (uC1M) were 
significantly increased (both P < 0.001). At 12 weeks, uC3M (P < 0.001) and uC1M (P < 0.01) further increased in ADR-
rats versus controls, just as fibronectin, PDGF-β receptor, hyaluronan (all P < 0.01), iColl3, PAS, myofibroblasts, mac-
rophages and T-cells (all P < 0.05). FTY720-treatment reduced accumulation of immune cells, α-SMA+ myofibroblasts 
and PAS-score, but not iColl3 and uC3M. Correlation analyses indicated that uC3M and uC1M reflected and predicted 
tubulointerstitial fibrogenesis.
Conclusions: These data displayed urinary collagen breakdown products as sensitive early markers of intersti-
tial fibrosis, preceding histological fibrotic changes, which might replace the invasive renal biopsy procedure to 
assess fibrosis. Anti-fibrotic FTY720 intervention reduced some fibrotic markers without affecting collagen type III 
metabolism.
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Background
Renal interstitial fibrosis (IF) is an important pathologi-
cal feature of disease progression in chronic kidney dis-
ease (CKD) [1, 2]. Despite its importance as a marker 
of disease progression, early detection and quantitative 
analysis of IF remains a challenge, both in the clinical and 
in the experimental setting. The most widely used and 
accepted clinical markers to predict the progression of 
CKD are the estimated glomerular filtration rate (eGFR) 
and albuminuria [3–5]. By the time these functional 
changes are detectable, advanced pathological structural 
changes have already taken place. Therefore it would be 
beneficial to be able to detect renal tissue remodeling 
earlier [6].
Currently, the gold standard to assess renal IF in 
CKD is performing a renal biopsy followed by a semi-
quantitative histological evaluation by a pathologist. 
This approach is however prone to sampling error and 
to intra- and inter-observer variability [7]. Many stud-
ies have tried to find non-invasive, more sensitive and IF 
specific alternatives. One of the most promising alterna-
tives are urinary markers, which are consequent of the 
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processes of extracellular matrix (ECM) production and 
degradation, thus reflecting fibrogenesis [6, 8].
Renal IF is characterized by an increased production 
and deposition of ECM, which eventually leads to a pro-
gressive loss of kidney function [9]. For tissue homeo-
stasis, it is important to maintain a balance between 
synthesis and degradation of ECM proteins. However, 
this equilibrium is delicate and when disrupted, it can 
lead to IF [10].
In terms of synthesis, (myo)fibroblasts with an acti-
vated phenotype expressing smooth muscle actin 
(α-SMA) are considered to be the main source of the 
increased deposition of ECM [11–15]. Earlier studies 
showed that interstitial fibrosis is the result of an increase 
in important ECM components, namely collagen type I, 
collagen type III, fibronectin and proteoglycans [16–18].
Collagen type I and III are major interstitial colla-
gens and their turnover is determined by, among other 
enzymes, matrix metalloproteinases (MMP), which are 
zinc-dependent enzymes and are synthesized in many 
tissues including the kidney [19–22]. During tissue 
remodeling, small protein fragments are released into the 
circulation, where these may be used as biomarkers. Two 
promising markers are generated by MMP-mediated col-
lagen type I and III degradation (C1M and C3M, respec-
tively) which have been shown to reflect renal IF [23–25].
In this study, our aim was to assess the diagnostic value 
for fibrosis of different collagen degradation products 
in the urine (uC1M and uC3M) and plasma (pC3M), as 
compared to (immuno)histological markers of fibrosis 
in a rat model of Adriamycin-induced nephropathy (i.e. 
a model of proteinuria-induced tubulointerstitial fibro-
sis). S1P receptor modulator FTY720 (FINGOLIMOD®) 
has been shown to have an inhibitory effect on fibrosis 
and on T cell mediated inflammation [26–29]. Therefore 
this intervention was used to distinguish the effects of 
anti-fibrotic treatment on different components of ECM 
remodeling pathways in the kidneys, as well as on colla-
gen fragments in plasma and urine.
In our well-established rat model proteinuria precedes 
fibrosis and allows prognostic evaluation of fibrotic 
markers in relation to the deposition and prevention of 
fibrosis.
Methods
Animal experiment and treatments
The detailed experimental setting has been described 
previously [30]. In short, twenty-eight 3-month old male 
Wistar rats were randomly divided in two groups. In the 
first group (ADR-rats; N = 16) proteinuria was induced 
by injecting Adriamycin in the tail vein (2  mg/kg body 
weight). The rats in the second group received a saline 
injection in the tail vein and served as healthy controls 
(HC; N = 12). Six weeks after the injections, renal biop-
sies were taken to evaluate renal structural damage as 
described before [31]. After 3 days of recovery, treatment 
with S1P-receptor modulator FTY720 (Novartis, Basel, 
Switzerland, 1  mg/kg body weight per day in drinking 
water) was started in the ADR group (ADR-FTY; N = 8) 
and in the control group (C-FTY; N = 6). Eight ADR-rats 
and six control rats remained untreated.
At 12  weeks, blood pressure was measured under 
general anesthesia with the Cardiocap/5 (Datex-Ohm-
eda, Newark, USA). Animals were then sacrificed and 
organs were harvested after saline perfusion. Renal tis-
sue obtained from the biopsy (6  weeks) and at sacrifice 
(12  weeks) was collected and partly preserved in for-
maldehyde 10% for paraffin embedment, and also snap-
froze stored at −80 °C for cryosectionting and qRT-PCR 
analyses.
At the beginning of the study, at the time of the biopsy 
(6 weeks), and at the end of the experiment (12 weeks), 
bodyweight was measured, blood samples were collected 
and rats were placed in metabolic cages for 24  h urine 
collection and the measurement of food and water intake. 
Proteinuria was determined in urine samples by a turbi-
dimetric assay (Roche Modular P, Mannheim,Germany). 
Urea and creatinine in plasma and urine were measured 
by an enzymatic UV assay (Roche Modular P).
The experiment was carried out under a protocol, 
which was approved by the Animal Care Committee of 
the University of Groningen (Licence Number 6318D).
Immunohistochemistry
Immunohistochemical staining was performed on 
4-μm-thick formalin-fixed paraffin sections after depar-
affinization in xylene and rehydration in alcohol series, 
or on 4-μm-thick cryo sections with acetone fixation. For 
paraffin sections; antigen retrieval was done for 15  min 
in a microwave oven for Tris/EDTA buffer pH:9.0 and 
citrate buffer pH:6.0, or overnight at 80  °C in Tris/HCl 
buffer pH:8.0. For paraffin and cryo sections; endogenous 
peroxidase activity was blocked with 0.3 or 0.03% hydro-
gen peroxide, respectively. Endogenous biotin binding 
sites were blocked by an Avidin/Biotin blocking step in 
case of biotin-labeled first antibodies. Sections were 
incubated for 1 h or overnight at 4 °C with the following 
primary antibodies: mouse anti-human α-smooth muscle 
actin (SMA) (clone 1A4, Sigma-Aldrich, St Louis, USA), 
goat anti-collagen type III (cat. no. 1330-01, Southern 
Biotech, Birmingham, USA), rabbit anti-rat CD3 (clone 
A0452, Dako, Glostrup, Denmark), biotinylated hyalu-
ronan binding protein (HABP, Seikagaku, Tokyo, Japan), 
mouse anti-rat CD68 (clone ED1, AbD Serotec, Oxford, 
UK), and rabbit mAb anti-platelet-derived growth factor 
(PDGF) Receptor β (28E1) (cat. No. 3169, Cell Signaling 
Page 3 of 11Hijmans et al. J Transl Med  (2017) 15:63 
Technology, Danvers, USA). After this step, the sections 
were incubated with secondary and tertiary antibod-
ies diluted in PBS/1% BSA and 1% normal rat serum. 
We used rabbit anti-mouse Ig horseradish peroxidase 
(HRP), goat anti-rabbit Ig HRP, goat anti-mouse Ig HRP, 
rabbit anti-goat Ig HRP, swine anti-rabbit HRP and anti-
rabbit poly HRP (all from Dako, Glostrup, Denmark). As 
negative controls, the primary antibodies were replaced 
by PBS/1% BSA. The negative controls were found to 
be negative. Bound antibodies were visualized by ami-
noethylcarbazole (AEC) or by the peroxidase substrate 
3,3-diaminobenzidine (DAB) (Sigma-Aldrich, St Louis, 
USA) and then counterstained with diluted hematoxylin. 
Biotinylated HABP was visualized using FITC-conjugated 
streptavidin (Invitrogen, Carlsbad, USA). DAPI (Vector 
laboratories, Burlingame, USA) was used to stain nuclei. 
The sections were scanned with a NanoZoomer HT digi-
tal scanner (Hamamatsu Photonics K.K., Shizuoka Pref., 
Japan). Fluorescence microscopy was performed using a 
Leica DMLB microscope (Leica Microsystems, Rijswijk, 
the Netherlands) equipped with a Leica DC300F cam-
era and Leica Qwin 2.8 software. The quantification 
was done using Aperio ImageScope software (version 
9.1.772.1570, Aperio Technologies Inc., Vista, CA, USA) 
and ImageJ 1.46r (Rasband, W.S., U.S. National Institutes 
of Health). ED1-positive macrophages and CD3-positive 
T cells were manually counted in 30 cortical interstitial 
fields per kidney. The expression of collagen type III, hya-
luronan, PDGF-β receptor and myofibroblasts (α-SMA) 
was measured by using an automatic quantification 
method using ImageJ 1.41 (Rasband, W.S., U.S. National 
Institutes of Health) and expressed as a % of positively 
stained area.
Renal morphology
Sections (4  μm) of formalin-fixed paraffin embedded 
kidneys were stained with Periodic Acid Schiff (PAS). 
Renal damage was semi-quantitatively scored on a scale 
ranging from 1 to 5. The scoring indicates which part of 
total renal cortical tissue was affected by tubulointersti-
tial fibrosis (PAS-positive broadening interstitial area in 
between the tubules): score 1: <1%; score 2: 1–5%; score 
3: 6–10%; score 4: 11–20%; score 5: 21–50%.
Use of published data by our group
The data on collagen III, alpha-SMA and PAS from Fig. 2 
were published before [30], however are necessary for 
comparison with the new stainings and quantifications of 
the other markers of fibrosis, namely fibronectin, PDGF 
Receptor beta and hyaluronan (see Fig. 2). Since the same 
authors are involved in both the previous as well as in the 
writing of this manuscript, permission was granted to use 
the data.
Plasma and urinary collagen degradation products
Supernatant from antibody producing hybridoma was 
collected and the monoclonal antibody was purified 
using HiTrap affinity columns (GE Healthcare Life Sci-
ence, Little Chalfront, Buckinghamshire, UK) and labeled 
with HRP using Lightning-Link™ HRP Conjugation 
Kit (Innova Biosciences, Babraham, Cambridge, UK), 
according to the manufacturer’s instructions.
The competitive ELISA procedures have been 
described in detail before [23, 24]. In short, procedures 
were as follows: Streptavidin coated plates were incu-
bated with 100  µl biotinylated-peptide for 30  min at 
20  °C. Plates were washed five times in washing buffer 
(20  nM TRIS, 50  mM NaCl, pH 7.2). Sample/standard/
control (20  µl) was added and followed immediately by 
addition of 100 µl HRP labeled monoclonal antibody and 
incubated for 1 h at 20  °C (pC3M), 3 h at 4  °C (uC1M), 
or 20  h at 4  °C (uC3M). After incubation, plates were 
washed five times in washing buffer. A volume of 100 µl 
3,3′,5,5′ -Tetramethylbenzidine (TMB) was added and 
incubated for 15  min at 20  °C in the dark. To stop the 
enzyme reaction of TMB, 100 µl 0.1% sulphuric acid was 
added and the plate was analyzed in the ELISA reader at 
450 nm with 650 nm as the reference (Molecular Devices, 
SpectraMax M, CA, USA). A calibration curve was plot-
ted using a 4-parametric mathematical fit model. Each 
ELISA plate included kit controls to monitor inter-assay 
variation. All samples were measured within the range 
of the specific assay. All samples below the lower limit 
of quantification (LLOQ) were assigned the value of 
LLOQ. The urinary markers were normalized for urinary 
creatinine.
Statistical analyses
Statistical analysis was performed using SPSS 20.0 
(SPSS Inc., Chicago, IL, USA) or Statsdirect 3.0 (Chesh-
ire, UK), and GraphPad Prism 5.0 (GraphPad Software 
Inc., La Jolla, CA, USA) was used to construct graphs 
and figures. Statistical differences between all groups 
at the same time-point were tested using the non-para-
metric unpaired Kruskall-Wallis test (with Dwass-Steel-
Critchlow-Fligner post-test) and differences over time by 
using the non-parametric paired Friedmann test (with 
Iman and Davenport post-test). Correlations were tested 
using the non-parametric Spearmann Rank test on the 
Z-scores of the variables used. Correlations between col-
lagen degradation markers at 12  weeks and histological 
markers at 6  weeks were tested using data of untreated 
ADR-rats only (N = 8). For correlations at between vari-
ables at the same time-point (12  weeks), we paired the 
FTY720-treated ADR-rats and the untreated ADR-rats 
(N = 16). Statistical differences of P < 0. 05 were consid-
ered significant.
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Results
Adriamycin induced proteinuria and tubulointerstitial 
remodeling
The effects of ADR on proteinuria and tubulointerstitial 
remodeling have been described in detail before [30]. In 
short a summary of the relevant results for our study: 6 
weeks after ADR injection proteinuria was increased 
eightfold up to 146 [77–230]  mg/24  h (P  <  0.001) com-
pared to controls (18 [13–27] mg/24 h). At this early time-
point, tubulointerstitial myofibroblasts started to appear, 
however, no interstitial collagen type III deposition was 
observed yet. Twelve weeks after ADR injection, pro-
teinuria further increased up to 338 [176–535] mg/24 h, 
which was associated with an increase in tubulointersti-
tial fibrosis (PAS), increased collagen type III deposition, 
and accumulation of myofibroblasts, macrophages (MΦ) 
and T-cells (all P  <  0.05). Treatment of ADR-rats from 
weeks 6 to 12 with FTY720 neither reduced proteinuria 
nor reduced renal collagen type III expression (both at 
protein and mRNA level). However, renal accumulation 
of myofibroblasts and T-cells were significantly lower 
after FTY720 treatment (both P  <  0.05) and apparently 
MΦ (NS). FTY720 also significantly reduced tubulointer-
stitial fibrosis score (PAS; P < 0.05).
Longitudinal analysis of plasma and urinary collagen 
degradation fragments
To assess the diagnostic and predictive value of non-inva-
sive collagen degradation fragments, we time-depend-
ently analysed the markers of ECM remodeling in healthy 
control rats and ADR-injected rats, both untreated and 
treated with S1P-receptor modulator FTY720.
The timecourse of untreated ADR-rats (Fig.  1. Left 
panels), showed a transient increase of pC3M 6 weeks 
after ADR injection (baseline vs week 6: P  <  0.01), that 
returned to baseline values at 12 weeks (Fig.  1a; weeks 
12 vs 6: P  <  0.001). uC3M values showed an ongoing 
increase at weeks 6 and 12 in ADR-rats compared to con-
trol values (Fig.  1c; both P  <  0.001). uC1M levels were 
significantly higher both at weeks 6 (P  <  0.001) and 12 
(P  <  0.01) in ADR-rats compared to their healthy con-
trols at the same time-points (Fig. 1e). These data showed 
increased excretion of uC1M and uC3M upon progres-
sion of proteinuria-induced tubulointerstitial fibrosis.
Treatment of healthy controls with FTY720 (Fig.  1. 
Right panels) showed a decreasing trend in pC3M over 
time, while FTY720-treated ADR-rats showed a sig-
nificant decrease at 12 weeks compared to baseline 
(P < 0.01) and 6 weeks (Fig. 1b; P < 0.001). uC3M levels 
in the FTY720-treated ADR-rats (Fig. 1d) increased sig-
nificantly over time at both 6 weeks (P  <  0.01) and 12 
weeks (P  <  0.001) compared to baseline values. uC1M 
levels in healthy controls treated with FTY720 showed 
a significant decrease over time at 6 (P  <  0.05) and 12 
weeks (P  <  0.001). At 12 weeks, FTY720-treated ADR-
rats showed significantly higher uC1M values compared 
to their controls at 12 weeks (Fig.  1f; P  <  0.05). Impor-
tantly, FTY720 treatment did not reduce excretion of 
both uC3M and uC1M in ADR-rats.
To dissect different fibrotic pathways, we also looked at 
specific fibrotic markers in the renal tissue and if these 
markers are affected by treatment with FTY720. At 6 
weeks, we did not see any significant changes for collagen 
type III expression, α-SMA positive myofibroblasts and 
tubulointerstitial fibrosis (PAS) in the renal tissue, which 
has been published before by our group and is needed to 
interpret our most recent findings [30].
At 12 weeks, ADR-rats showed an increase in collagen 
type III expression (Fig.  2 first row; P  <  0.05), α-SMA 
positive myofibroblasts (Fig.  2 third row; P  <  0.05) and 
tubulointerstitial fibrosis by PAS staining (Fig.  2 fifth 
row; P  <  0.05) compared to controls, while treatment 
with FTY720 showed a (non-significant) decrease of the 
expression of α-SMA positive myofibroblasts and tubu-
lointerstitial fibrosis (PAS score), which can no longer 
be differentiated from FTY720-treated control rats. The 
expression of fibronectin showed the same trend as col-
lagen type III expression increased significantly in ADR-
treated rats compared to controls (Fig.  2 second row; 
P < 0.01). Treatment with FTY720 did not have an effect 
on the expression of fibronectin.
In order to investigate α-SMA positive myofibroblasts 
as a possible pro-fibrotic marker, we compared these 
findings to the expression of the PDGF-β receptor as an 
alternative phenotypic fibroblast marker. The expression 
of PDGF-β receptor was increased in ADR-rats com-
pared to controls (Fig.  2 fourth row; P  <  0.01), whereas 
α-SMA positive myofibroblasts influx decreased under 
treatment with FTY720, there was no significant differ-
ence in PDGF-β receptor expression between untreated 
ADR-rats and FTY720-treated ADR-rats.
To investigate if the apparent reduction in tubuloint-
erstitial fibrosis (PAS) between untreated and FTY720-
treated ADR-rats might be an effect of FTY720 on the 
accumulation of glycosaminoglycans instead of reflect-
ing the collagen metabolism, a staining for hyaluronan 
was done. This staining showed the same non-signifi-
cant decrease in the FTY720-treated ADR group as was 
shown by the PAS (Fig. 2 sixth row), corroborating that 
positive PAS staining represents glycosaminoglycans 
rather than collagens. Based on the quantification of 
various (immuno)histochemical markers we conclude 
that the FTY720 intervention tended to reduce accu-
mulation of a-SMA positive myofibroblasts, hyaluronan 
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and the fibrosis score based on PAS-staining. However, 
FTY720 treatment did not reduce the (myo)fibroblast 
marker PDGF-β receptor, interstitial collagen type III and 
fibronectin.
uC3M forebodes the development of renal fibrosis
uC3M and uC1M at week 6 did not show any correlation 
with histological markers at the same time-point in all 
ADR-rats (not shown). However, uC3M at 6 weeks was 
Fig. 1 Effects of Adriamycin with or without FTY720 treatment on collagen degradation markers. Effects of Adriamycin are shown without (left 
panels) and with FTY720 treatment (right panels) on pC3M (a, b), uC3M (c, d), and uC1M (e, f). uC3M and uC1M concentrations were expressed per 
mg urinary creatinine. Open boxes represent controls, dark grey boxes ADR-rats. *P < 0.05, **P < 0.01, ***P < 0.001. Statistical differences between 
all groups at the same time-point were tested using the Kruskall-Wallis test (Dwass-Steel-Critchlow-Fligner post-test) and differences over time by 
using the Friedmann test (Iman and Davenport post-test)
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associated with hyaluronan at 12  weeks and borderline 
with the PAS fibrosis score at 12 weeks in the untreated 
ADR-rats, but not with the other renal fibrosis markers 
(Table 1A). In addition, uC1M at 6 weeks associated bor-
derline significance with the PAS-score at 12  weeks in 
untreated ADR-rats.
At 12 weeks, after pooling of both the ADR-untreated 
as well as in FTY720-treated ADR-rats (N = 16), uC3M 
was strongly associated with renal collagen type III, 
myofibroblast density, PDGF-β receptor, tubulointer-
stial fibrosis (PAS) and hyaluronan. uC1M showed the 
same associations, except for collagen type III (Table 1B). 
These associations indicate that uC3M and uC1M rep-
resent and predict early development of renal fibrosis, 
at least in this experimental model of proteinuria-driven 
renal fibrosis.
Discussion
The novel finding in this study is that uC3M is measur-
able prior to being histologically detectable, making it 
an early non-invasive predicting marker for renal fibro-
sis. Furthermore, collagen type I and III degradation 
(C1M and C3M) are late urinary markers reflecting the 
extent of established renal fibrosis. Dissection of different 
fibrotic pathways using S1P-modulator FTY720 showed 
that uC3M was more specific in reflecting renal fibrosis, 
in terms of collagen deposition, compared to the more 
commonly used PAS or α-SMA staining.
Proteinuria developed 6 weeks after Adriamycin 
injection in rats but collagen type III deposition was 
not observed at this time-point [30]. uC3M and uC1M 
were significantly elevated compared to the controls at 
6 weeks. The uC3M results were profoundly elevated 
Table 1 Predictive value of uC3M and uC1M at 6 (A) weeks and correlation at 12 weeks (B) with histological fibrotic mark-
ers at week 12 in untreated ADR-rats and FTY720-treated ADR-rats
Significant differences are highlighted in italics. Spearmann rank correlation was done on Z-values of all variables
uC3M/Cr 6 weeks uC1M/Cr 6 weeks
Rs P value Rs P value
A.
 ADR untreated rats
  Histological markers—12 weeks
   Collagen type III 0.381 0.352 0.262 0.531
   Fibronectin 0.238 0.570 0.190 0.651
   Myofibroblasts(α-SMA) 0.333 0.420 0.310 0.456
   PDGF-β receptor 0.524 0.183 0.405 0.320
   Tubulointerstitial fibrosis (PAS) 0.687 0.060 0.674 0.067
   Hyaluronan 0.810 0.015 0.571 0.139
uC3M/Cr 12 weeks uC1M/Cr 12 weeks
Rs P value Rs P value
B.
 ADR-rats (pooled)
  Histological markers—12 weeks
   Collagen type III 0.529 0.035 0.403 0.122
   Fibronectin 0.074 0.787 0.194 0.471
   Myofibroblasts(α-SMA) 0.600 0.014 0.497 0.050
   PDGF-β receptor 0.841 <0.0001 0.656 0.006
   Tubulointerstitial fibrosis (PAS) 0.831 0.000 0.694 0.003
   Hyaluronan 0.807 0.000 0.654 0.006
(See figure on previous page.) 
Fig. 2 Effects of FTY720 treatment on tubule-interstitial remodeling at week 12. Expression of interstitial collagen type III (×400), fibronectin (×200), 
α-SMA positive myofibroblasts (×200), PDGF-β receptor (×200), interstitial fibrosis (PAS; ×200) and hyaluronan (×400) at week 12. Data of collagen 
type III, α-SMA and PAS have been published before [30]). Permission to show data was granted by the authors and publishers. *P < 0.05, **P < 0.01, 
***P < 0.001. Statistical differences between groups were tested using the Kruskall-Wallis test (Dwass-Steel-Critchlow-Fligner post-test)
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and therefore we measured plasma C3M as well and 
found a significant transient peak at 6 weeks compared 
to baseline and 12-week values. Karsdal et  al. previ-
ously showed an age-related transient peak of pC3M at 
8 weeks, which is around the same time-point where we 
found a transient peak of C3M as well (i.e. at 6  weeks) 
[32]. The data suggest that at 6 weeks, tissue remodeling 
had started and although no collagen deposition could 
be demonstrated at this early time-point, both urinary 
and plasma values of C1M and C3M were increased. 
This suggests active tissue remodeling, which most likely 
reflects a pre-fibrotic event. From weeks 6 to 12, inter-
stitial fibrosis developed, uC1M remained elevated and 
uC3M increased even further. The reduction in the lev-
els of uC3M and uC1M in the control untreated animals 
could be due to an age effect which has been described 
previously by Karsdal et al. [32]. Anti-fibrotic treatment 
with S1P modulator FTY720 (FINGOLIMOD®) yielded 
mixed results for the various fibrotic markers quantified 
in the kidneys. It appears that the kinetic response of the 
various fibrotic pathways varies with anti-fibrotic ther-
apy. uC3M appears to be an early and sensitive marker of 
renal tissue remodeling.
In order to dissect different fibrotic pathways, we 
looked at the effect of anti-fibrotic treatment with 
FTY720 on different histological markers, which are fre-
quently used (both in the clinic or for research purposes) 
to address renal fibrosis [7]. Previously published results 
on collagen type III expression, α-SMA positive myofi-
broblasts and tubulointerstitial expression (PAS), showed 
that treatment with FTY720 had different effects on these 
markers, even though all are known to reflect renal fibro-
sis [30]. The role of the extracellular matrix as a mere 
scaffold to uphold tissue integrity is being questioned, 
and it is becoming increasingly clear that it may be con-
sidered as a complex paracrine/endocrine entity [33]. 
Previous studies showed that structural proteins, such as 
collagens, do not only have organizational properties, but 
might also have other effects. For example, collagen type 
I, collagen type III and fibronectin are involved in signal-
ing pathways during fibrosis and inflammation by activat-
ing hepatic stellate cells (reviewed in [33]). The dissection 
of the different components of ECM remodeling by anti-
fibrotic and anti-inflammatory FTY720-treatment allows 
us to have a more specific look at the roles of the most 
important involved structural proteins.
To investigate these different outcomes and in order 
to define what kind of fibrotic pathway is reflected by 
increased uC3M, we furthermore performed staining 
for fibronectin (as a ECM marker which is able to bind 
to collagen), for the PDGF-β receptor (as an alterna-
tive fibroblast marker) and for hyaluronan (as a matrix 
glycosaminoglycan, GAG) [34–36]. Interestingly, 
fibronectin showed the same pattern as collagen type 
III. Findings were confirmed by previously published 
qPCR results, where treatment with FTY720 did not 
have a significant effect on collagen type I, collagen 
type III or TGF-β mRNA expression [30]. The expres-
sion of the PDGF-β receptor was unchanged after 
FTY720 treatment and clearly deviates from α-SMA 
positive myofibroblasts. There are different subpopu-
lations of myofibroblasts and the finding that FTY720 
lowered α-SMA positive myofibroblasts and did not 
have an effect on PDGF-β receptor-expressing fibro-
blasts suggests that there might be a shift in the popula-
tion of fibroblasts or that the myofibroblasts lose α-SMA 
expression upon FTY720 treatment. PAS staining also 
showed a contrasting pattern compared to collagen type 
III expression after FTY720 treatment. PAS is used as a 
fibrotic marker, and specifically stains acid groups [37]. 
Therefore, we investigated if the decrease of PAS could 
be explained by a decreased glycosaminoglycan expres-
sion which are ECM compounds containing acid car-
boxyl groups. Staining was done for hyaluronan, which 
showed the same decrease after FTY720 treatment as 
PAS, confirming our hypothesis that the decrease of PAS 
staining after FTY720 treatment reflects a direct effect of 
FTY720 on the level of proteoglycans/GAGs.
The data suggest that treatment with FTY720 influ-
ences the differentiation of myofibroblasts by loss of 
α-SMA expression, without affecting the expression of 
the PDGF-β receptor. This showed no effect on the col-
lagen and fibronectin metabolism. It however does influ-
ence GAGs as hyaluronan expression decreases and this 
consequently reduces the PAS fibrosis-score.
We were interested in the diagnostic and predictive 
value of uC3M and uC1M. At 6 weeks uC3M in the 
untreated ADR-rats showed a positive correlation with 
hyaluronan at 6 and at 12 weeks. At 6 weeks uC1M and 
uC3M were borderline significantly correlated with the 
PAS fibrosis score at 12  weeks. At 12 weeks uC1M and 
uC3M were associated with most of the fibrotic kidney 
markers at 12  weeks. These data indicated that early 
uC3M, and to a lesser extent uC1M, precede and reflect 
renal fibrosis.
The strength of this study is the well-established time 
course in which we were able to follow changes in both 
histological renal remodeling responses, as well as in 
urinary/plasma degradation products at different time-
points. This allowed us to show that uC3M is elevated at 
an earlier time-point compared to histological collagen 
type III expression [6, 25]. Another strength is the dissec-
tion of the different fibrotic pathways by using FTY720 
treatment, showing a deviation in collagen and hyalu-
ronan tissue responses. We were thus able to show that 
uC3M reflects the level and predicts future deposition of 
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type III collagen. Our data showed that uC3M is an early 
fibrotic marker for collagen type III deposition, but not 
representative for other ECM components.
During physiological conditions remodeling of the 
ECM is very low but increases during injury. Increased 
degradation is promoted by a rise in protease activity 
such as by MMPs [38]. Protease-generated fragments 
of a protein have been suggested to be more specific for 
pathological ECM turnover during fibrosis than total 
protein content since it is dependent on the local pro-
tease activity [39]. The C1M and C3M assays are highly 
specific which allows us to assess collagen degradation by 
MMPs, a process believed to be associated with the path-
ological turnover of the ECM during fibrosis [40]. To our 
knowledge, no comparable assay is currently available or 
published. Commercial assays for measurements of col-
lagens in serum or urine are not directed against specific 
epitopes, but rather utilize polyclonal antibodies.
When we compare our results to what was found in 
humans, we found that uC3M decreases in humans with 
increasing disease severity, while it increases in rats [41]. 
The proces of fibrosis exist of both fibrogenesis and colla-
gen degradation. In the early disease stages (as been shown 
in our animal model), fibrogenesis and collagen degrada-
tion balance eachother out and only when the disease pro-
gresses, fibrogenesis become more apperent compared 
to degradation and fibrotic laesions start to appear [42]. 
The fact that during disease progression the balance tips 
towards fibrogenesis can be explained by the fact that col-
lagens are known to crosslink [43–45] and can become 
inaccessible for cleavage of collagens by MMPs [20, 38, 
46]. Next, Di Donato et  al. investigated the renal expres-
sion of lysyl oxidase and its effects on collagen cross-link-
ing at various stages of chronic Adriamycin nephropathy 
in rats [47]. They showed that mRNA levels of lysyl oxi-
dase increase up to 3 times in the ADR-rats compared to 
controls between 8 and 12 weeks, and the levels reduced 
to normal levels at 16 weeks. They demonstrated that an 
increased expression of lysyl oxidase in the kidney pre-
cedes the development of diffuse fibrotic lesions and that, 
at this stage, collagenic structures contain highly cross-
linked components, the final product of lysyl oxidase 
activity. In our study, we only measured levels of collagen 
degradation markers between 6 and 12 weeks after ADR-
injection, the period when lysyl oxidase levels are increas-
ing, but collagen crosslinking has just begon and is not at 
his final stage. Lysyl oxidase has also been shown to be 
involved in fibrosis in humans [48, 49]. In patients with 
CKD the disease is present for longer then 6–12 weeks and 
collagen crosslinking is already occurring in abundance, 
making it hard for MMPs to degradate the collagens. This 
is reflected by the decreasing urinary C3M levels during 
disease progression [41]. In this study we are looking for a 
possible early marker for renal fibrosis, which could be the 
collagen degradation fragments in the urine, since they can 
already be found before the balance between renal fibro-
genesis and collagen degradation is lost.
Possible limitations of this study are the previously used 
data, the pre-dominant interest in C3M in comparison to 
C1M, and the disease model. We have limited the re-use 
of our previously published data to the IHC data on colla-
gen type III, PAS and α-SMA. However, we need this data 
to understand the new findings better. In our previous 
study [30] we first found these contrasting findings on col-
lagen type III metabolism and the effects of anti-fibrotic 
FTY720 treatment on PAS and myofibroblasts. In this 
study, where we investigated if urinary collagen degrada-
tion fragments could be a good alternative for these inva-
sive histological diagnostic markers for renal fibrosis, we 
found this very interesting novel finding that these urinary 
collagen degradation markers can be shown in the urine 
prior to any visible histological changes. While the need 
for good diagnostic, prognostic and next to this clinical 
applicable biomarkers is growing, we tried to investigate 
the different fibrotic pathways to further detail in order to 
get a better understanding of the specificity of the colla-
gen degradation markers and the prognostic properties.
We found the most profound differences in the urinary 
C3M levels and the urinary C1M levels showed the same 
trends as urinary C3M. We choose to add the C1M data 
on urine to underline that the possibility of collagen deg-
radation markers in the urine during renal fibrosis is not 
limited to collagen type III degradation fragments, but 
can also be found for collagen type I degradation frag-
ments. At least in this study.
Next to this, we realize that the Adriamycin nephrop-
athy model is driven by proteinuria. We therefore can 
not be absolutely certain whether the increased levels of 
uC1M and uC3M are due to increased glomerular filtra-
tion or if it is an effect of an increased turnover of renal 
type I and III collagen. However, in a previously published 
study collagen degradation fragments C1M and C3M 
were measured in three different rat models for nephrop-
athy, namely renal mass reduction (5/6 nephrectomy), 
progressive glomerulonephritis (chronic anti-Thy1.1 
nephritis) and adenine crystal-induced nephropathy. 
All three treatments caused significant renal fibrosis on 
a histological level and showed a significant increase of 
both uC3M and uC1M. Interestingly, while the adenine 
model caused the most profound increasing effect on the 
levels of uC3M and uC1M compared to the other mod-
els, it was not accompanied by proteinuria [25]. This 
underlines our hypothesis that the urinary collagen deg-
radation fragments primarily reflect renal fibrogenesis 
and makes it unlikely that the increase in uC3M is mainly 
attributable to the proteinuria.
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Conclusions
In conclusion we described the greater diagnostic and 
predictive value of urinary collagen degradation markers 
C3M and C1M compared to the more conservative his-
tological markers in a rat model of Adriamycin-induced 
nephropathy. We investigated the specificity of uC3M 
as a marker for renal fibrosis, by dissecting the collagen 
fibrotic pathway from other fibrotic pathways using anti-
fibrotic S1P-receptor modulator FTY720. Although fur-
ther research is needed to investigate the predictive value 
of the urinary collagen degradation markers, we propose 
that the diagnostic and predictive use of urinary colla-
gen degradation markers to assess renal fibrosis can be 
used in early stages during disease progression of differ-
ent etiologies. It might be used as a better, safer and more 
patient-friendly alternative than the renal biopsy, which 
is an invasive way of assessing histological markers of 
fibrosis.
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